Pharming Group (PHGUF) Upgraded to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Pharming Group (NASDAQ:PHGUF) from a hold rating to a buy rating in a research note published on Wednesday. Zacks Investment Research currently has $0.25 price objective on the stock.
According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “
Shares of Pharming Group (NASDAQ:PHGUF) opened at 0.25 on Wednesday. The stock has a 50 day moving average of $0.00 and a 200 day moving average of $0.00. The firm’s market cap is $103.15 million. Pharming Group has a 52 week low of $0.17 and a 52 week high of $0.35.
About Pharming Group
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.
Receive News & Stock Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related stocks with our FREE daily email newsletter.